Gland Pharma's Q3 FY26: A Quarter of Robust Growth and Strategic Execution

Gland Pharma Limited, a prominent player in the generic injectable-focused pharmaceutical sector, has reported a strong performance for the third quarter ended December 31, 2025. The company's consolidated revenue from operations surged by an impressive 22% year-on-year, reaching INR 1,695.4 crores. This robust top-line growth was complemented by a significant improvement in profitability, with adjusted Profit After Tax (PAT) climbing 37% year-on-year to INR 279.7 crores. The quarter's results underscore the company's disciplined execution across its diverse business segments, including the successful turnaround of its European subsidiary, Cenexi.

Mr. Srinivas Sadu, Executive Chairman of Gland Pharma, highlighted that the strong Q3 FY26 performance, marked by healthy adjusted EBITDA margins of 26%, reflects effective execution. He expressed confidence in sustaining this momentum, driven by new product launches, ramp-up of CDMO contracts, and contributions from new capacities. Mr. Shyamakant Giri, Chief Executive Officer, further emphasized that the double-digit growth across key markets like the US and Europe, coupled with steady margin improvements and Cenexi reaching breakeven, were pivotal to the consolidated performance.

Segmental Performance and Market Dynamics

Gland Pharma's growth in Q3 FY26 was broad-based across its key markets. The US market, a significant contributor, saw its revenue grow by 19% year-on-year to INR 868.5 crores. This growth was fueled by the launch of nine new molecules during the quarter, including Argatroban, Acetazolamide, and Doxycycline. However, the volume growth of 19% compared to the revenue growth of 16% indicates persistent pricing pressure in the US market, necessitating continuous cost efficiency measures.

Europe emerged as a high-growth region, with revenue soaring by 54% year-on-year to INR 407.1 crores. This impressive performance was partly attributed to the strong top-line growth from Cenexi. Other core markets, including Canada, Australia, and New Zealand, experienced a slight dip of 1% year-on-year in Q3 FY26, though the nine-month period showed an 18% growth. India's business also demonstrated strong growth, increasing by 32% year-on-year to INR 74.4 crores, contributing 6% to the total base revenues. The Rest of the World market grew by 4% year-on-year to INR 300 crores.

Consolidated Financial Summary (Q3 FY26 vs Q3 FY25)

Cenexi's Turnaround and Strategic Initiatives

Cenexi, Gland Pharma's European subsidiary, delivered a strong performance, achieving revenues of EUR 50 million (INR 516.4 crores) and a positive EBITDA of EUR 1 million (INR 14.8 crores) in Q3 FY26. This marks a significant turnaround, driven by increased capacity utilization, contract renegotiations, workflow rationalization, and deeper operational integration. The company is investing in a new high-capacity ampoule line at its Fontenay facility, expected to add 30 million units by 2027. Additionally, a new vial line under isolator and a combo line for prefilled syringes and cartridges are planned for installation at the Braine-l'Alleud site in 2026, further enhancing manufacturing capabilities.

Consolidated Revenue by Geography (Q3 FY26)

Beyond Cenexi, Gland Pharma is making substantial investments in its core business. The company plans a Brownfield expansion with an investment of INR 2,000 crores over the next five years, focusing on BFS and ophthalmic lines, lyophilizers, and additional warehouse capacity. This expansion is critical to support the growing demand and the shift towards complex, high-value products. The company's R&D investments increased to 5.4% of revenues, primarily targeting complex injectables, advanced delivery systems, and platform-based development, resulting in 9 ANDA filings and 4 approvals in Q3 FY26.

Future Outlook and Management Confidence

Management expressed strong confidence in sustaining growth momentum, projecting an overall company growth of 12%-13% and an organic CAGR of 15% over the next five years. The aggressive expansion of Pen/cartridge capacity from ~40 million to 140 million units is strategically aimed at capitalizing on the burgeoning GLP-1 and insulin analog markets. Furthermore, the signing of a complex Nano Drug Delivery System based Injectable contract in Oncology with a Big Pharma, with commercialization anticipated by Q3/Q4 FY28, provides clear revenue visibility and strengthens the company's CDMO portfolio.

Cost efficiency remains a key priority, with initiatives focused on yield improvement, alternate vendor development, and automation expected to deliver 1-2 percentage points in savings. These measures are crucial for maintaining healthy margins amidst pricing pressures. Gland Pharma's strategic direction is clear: to evolve into a global innovation-led injectable and CDMO company that consistently delivers revenue growth, margin expansion, and superior capital efficiency. The Q3 FY26 results reaffirm this strategic path and the company's ability to deliver sustained value for its shareholders.